Abbott Laboratories stock faces a strategic test after Nutrition plan

Abbott Laboratories announced on October 21, 2026, that it intends to separate its global Nutrition business into an independent publicly traded company. The plan, described in the Abbott MediaRoom announcement, targets completion by the end of 2027.

Two businesses, different priorities

The planned company would include Similac, PediaSure, Pedialyte, Glucerna and Ensure. Abbott says the business would have approximately 8.5 billion US dollars in annual sales, about 16,000 employees and 14 manufacturing sites.

The transaction is intended to use a tax-free distribution of shares to Abbott shareholders. After completion, investors would own shares in both companies, while Daniel Salvadori is expected to lead the independent Nutrition business. The separation remains subject to regulatory approvals, an effective Form 10 registration statement and final approval by Abbott's board.

What has changed since our last report

Abbott Laboratories stock traded at 100.45 euros on Lang & Schwarz at 16:31 CET on Wednesday, November 4, 2026.

The latest quote is 1.88 percent above the 98.60 euros recorded in the previous report on Wednesday, November 4, at 13:08 CET. This intraday move gives the latest report a fresh market angle while the corporate plan itself remains unchanged.

Abbott expects to retain approximately 42 billion US dollars in annual sales after the separation, focusing on medical devices, biowearables, diagnostics and established medicines. The company says the planned transaction will not affect its 2026 guidance or the 2027 outlook expected in January, although one-time separation charges will arise before completion.

Investors can follow the real-time quote of Abbott Laboratories stock while the company advances the separation timetable.

Broader sentiment for US healthcare shares can be followed through the S&P 500.

Further updates will center on regulatory filings, the separation timetable and Abbott's 2027 guidance. More news and analyses on Abbott Laboratories stock will track these milestones.